Table 5: Adjusted OR after multivariate analysis for predictors of treatment outcome of completed treatment.

Characteristics Completed treatment Other treatment categories aOR(95% CI)p-value
N (%)N (%)

Baseline sputum smear
 (i) Yes32(15.2)178(84.8)2.09(0.66-6.61)0.210
 (ii) No7(8.0)81(92.0)

Baseline sputum culture
 (i) Yes22(14.3)132(85.7) 1.25(0.47-3.29) 0.654
 (ii) No9(9.1)90(90.9)

HIV status
 (i) Yes15(12.9)101(87.1)0.99(0.43-2.29)0.977
 (ii) No28(13.0)188(87.0)

Isoniazid
 (i) Resistant16(12.3)114(87.7) 1.17(0.41-3.33) 0.765
 (ii) susceptible2(18.2)9(81.2)

Rifampicin
 (i) Resistant26(12.9)176(87.1) 1.56(0.55-4.43) 0.405
 (ii) Susceptible1(20.0)4(80.0)

Streptomycin
 (i) Resistant9(11.3)71(88.8) 0.31(0.08-1.26) 0.101
 (ii) Susceptible4(11.8)30(88.2)

Ethambutol
 (i) Resistant7(9.6)66(90.4)2.49(0.68-9.03)0.166
 (ii) susceptible6(16.2)31(83.8)